Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
pulocimab (AK109)
i
Other names:
AK109
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Akesobio
Drug class:
VEGFR-2 inhibitor
Related drugs:
‹
rivoceranib (82)
ramucirumab (59)
RAF265 (7)
SU5614 (6)
tivozanib (3)
GSK1363089 (2)
GB-103 (2)
KC1036 (1)
OSI-930 (1)
BMS-582664 (1)
E7050 (1)
pegdinetanib (0)
BMS690514 (0)
BTG-002814 (0)
C019199 (0)
JI-101 (0)
JY025 (0)
MG-D-1509 (0)
MSB0254 (0)
NCE 401 (0)
R1530 (0)
VEGFR2-169 (0)
VXM01 (0)
DCC-2701 (0)
Gensci048 (0)
gentuximab (0)
TTAC-0001 (0)
TSU-68 (0)
SYHA1817 (0)
ASA404 (0)
rivoceranib (82)
ramucirumab (59)
RAF265 (7)
SU5614 (6)
tivozanib (3)
GSK1363089 (2)
GB-103 (2)
KC1036 (1)
OSI-930 (1)
BMS-582664 (1)
E7050 (1)
pegdinetanib (0)
BMS690514 (0)
BTG-002814 (0)
C019199 (0)
JI-101 (0)
JY025 (0)
MG-D-1509 (0)
MSB0254 (0)
NCE 401 (0)
R1530 (0)
VEGFR2-169 (0)
VXM01 (0)
DCC-2701 (0)
Gensci048 (0)
gentuximab (0)
TTAC-0001 (0)
TSU-68 (0)
SYHA1817 (0)
ASA404 (0)
›
Associations
News
Trials
Filter by
Latest
6ms
AK109-201: A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
P1/2, N=138, Recruiting, Akeso | N=87 --> 138 | Trial completion date: Jan 2024 --> Jan 2027 | Trial primary completion date: Jul 2023 --> Oct 2025
6 months ago
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
paclitaxel • Kaitanni (cadonilimab) • pulocimab (AK109)
6ms
A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
P3, N=506, Recruiting, Akeso | Not yet recruiting --> Recruiting
6 months ago
Enrollment open • Metastases
|
paclitaxel • Kaitanni (cadonilimab) • pulocimab (AK109)
8ms
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=198, Recruiting, Akeso | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Feb 2023 --> Dec 2024
8 months ago
Trial completion date • Trial primary completion date • Metastases
|
Kaitanni (cadonilimab) • pulocimab (AK109)
9ms
A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
P3, N=506, Not yet recruiting, Akeso
9 months ago
New P3 trial
|
paclitaxel • Kaitanni (cadonilimab) • pulocimab (AK109)
2years
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=198, Recruiting, Akeso | Trial completion date: Oct 2023 --> Mar 2024 | Trial primary completion date: Aug 2022 --> Feb 2023
2 years ago
Trial completion date • Trial primary completion date • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Kaitanni (cadonilimab) • pulocimab (AK109)
3years
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=198, Recruiting, Akeso
3 years ago
Clinical • New P1/2 trial • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Kaitanni (cadonilimab) • pulocimab (AK109)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login